Pangenia's News Updates

2020.07.28

Pangenia and OHSU Knight Diagnostic Laboratory collaborate to provide pathological and molecular reference laboratory services

With a mutually desirable agreement to provide quality oncology screening and diagnostic services, Pangenia Inc. (Pangenia), a leading molecular diagnostic company based in Hong Kong, and the OHSU Knight Diagnostic Laboratory (KDL), a division of the Knight Cancer Institute at Oregon Health & Science University, the only National Cancer Institute-designated Comprehensive Cancer Center between Sacramento and Seattle, have announced a new collaboration to deliver seamless molecular solutions in oncology and haematology settings. The agreement gives Pangenia’s patients and affiliated healthcare providers expedited access to the world-class, fully-licensed and accredited laboratory services at the KDL.

In addition, Dr. Christopher Corless, who leads the College of American Pathologists (CAP)- and Clinical Laboratory Improvement Act (CLIA)-accredited KDL as the executive director and chief medical officer, will share his expertise in molecular diagnostics and cancer pathology with Pangenia as a consulting specialist. Together, the two organizations will work to ensure the delivery of the absolute best in service quality to patients with cancer.

This collaboration will further solidify the leading role of Pangenia in cancer screening and molecular diagnostics, and will help more patients and healthcare providers access this extended array of services.